ArticleOsteoarthritis and cartilage open2026
A consumer co-designed community physical activity program for Australians living with osteoarthritis (CASCADE-OA): A randomised controlled trial protocol.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This protocol will detail the methodology of the CASCADE-OA trial that will determine the effectiveness of an evidence-based and co-designed walking program, Walk with Ease Australia in increasing physical activity levels in people with osteoarthritis (OA). Design: We will undertake a two-arm parallel assessor blinded RCT in a hybrid type 1 effectiveness-implementation design. 414 participants with a clinical diagnosis of knee or hip OA will be recruited across Australia through state and territory arthritis consumer advocacy groups, an OA management program in a public hospital setting, and social media. Participants with co-existing inflammatory arthritis or those already meeting physical activity guidelines will be excluded. Participants will be randomised 1:1 into either the Walk with Ease Australia + Fitbit™ group (intervention) or the Fitbit™ only group (comparator). The intervention period will be 12 weeks and participants will be followed for 12 months from randomisation. The primary outcome is average daily step count at 12 weeks as assessed by Fitbit™. Secondary outcomes include pain, disability, quality of life, self-efficacy, work absenteeism and healthcare utilisation. Implementation outcomes will be collected based on the RE-AIM framework domains and process evaluation framework for complex interventions. Results: The trial was registered on the Australia and New Zealand Clinical Trials Registry (ACTRN12625000185460) on February 17th, 2025 and received ethics approval from the Northern Sydney Local Health District Human Research Ethics Committee (2024/ETH01898). Conclusion: CASCADE-OA will determine whether Walk with Ease Australia will support people in the community with OA in increasing physical activity and improving symptoms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.